1234491-75-8

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-neopentyl 2-((tert-butoxycarbonyl)amino)propanoate is used as a reagent in the synthesis of amino acid derivatives and peptide-based compounds. Its stability and compatibility with other reagents make it a valuable component in the development of new drugs and pharmaceuticals.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-neopentyl 2-((tert-butoxycarbonyl)amino)propanoate is utilized as a key intermediate for the creation of various complex organic molecules. Its unique structure and reactivity contribute to the synthesis of a wide range of compounds with potential applications in different industries.
Used in Drug Development:
(S)-neopentyl 2-((tert-butoxycarbonyl)amino)propanoate is employed as a prodrug in drug development, where it is metabolized within the body to release the active pharmaceutical agent. This property allows for the design of drugs with improved bioavailability, reduced side effects, and targeted delivery to specific tissues or organs.
Used in Research and Development:
In the research and development sector, (S)-neopentyl 2-((tert-butoxycarbonyl)amino)propanoate is used as a starting material for the exploration of new chemical reactions and the synthesis of novel compounds with potential applications in various fields, including medicine, agriculture, and materials science.

Upstream product

• 75-84-3 2,2-dimethyl-propanol-1 
• 3744-87-4 Boc-(R)-Ala 
• 15761-38-3 L-N-Boc-Ala 

Downstream Products

• 1434144-66-7 (2S)-neopentyl 2-((naphthalen-1-yloxy)(4-nitrophenoxy)phosphorylamino)propanoate 
• 946511-98-4 (S)-1-(neopentyloxy)-1-oxopropan-2-aminium chloride 
• 125511-59-3 (S)-neopentyl 2-((tert-butoxycarbonyl)amino)propanoate 

Relevant academic research and scientific papers

ANTIVIRAL COMPOUNDS

The present disclosure describes 4'-fluoromethyl nucleosides for treating viral infections, including Dengue.

NUCLEOTIDE PRODRUGS

The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates using the prodrugs of the invention in the treatment of mitochondrial DNA (mtDNA) depletion syndrome (MDS).

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:wherein B is a nucleobase selected from the groups (a) to (d):and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

NUCLEIC ACID PRODRUGS

The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel prodrugs of the invention.

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) wherein B is a nucleobase selected from the groups (a) to (d) and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS

Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.